OncoMatch/Clinical Trials/NCT07402915
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Is NCT07402915 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including AZD5335 and Itraconazole for fallopian tube cancer.
Treatment: AZD5335 · Itraconazole — The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
have received at least 1 prior line of platinum-containing chemotherapy and have progressed on or within 6 months after the date of the last dose of platinum
Must have received: VEGF inhibitor (bevacizumab)
must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible
Must have received: PARP inhibitor
must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07402915 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and VEGF inhibitor.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages